Aldeyra的干眼药 得到了FDA的批准审查, 在AbbVie的交易中, 可能得到400万美元。 Aldeyra's dry eye drug gets FDA approval review, with potential for $400M in AbbVie deals.

艾尔德伊拉治疗公司的新药申请,用于治疗干眼病,已被FDA接受,审查截止日期为2025年4月2日. Aldeyra Therapeutics' new drug application for reproxalap, aiming to treat dry eye disease, has been accepted by the FDA with a review deadline of April 2, 2025. 该公司还扩大了与AbbVie的协议,这可能导致预付1亿美元,如果药物获得批准,达到3亿美元的里程碑。 The company also expanded its agreement with AbbVie, which could lead to a $100 million upfront payment and up to $300 million in milestones if the drug is approved. AbbVie将在美国处理60%的利润和损失,Aldeyra得到40%的收益。 AbbVie would handle 60% of profits and losses in the U.S., with Aldeyra receiving 40%.